US Court of Appeals upholds Shire's Vyvanse patent

25 September 2015

Ireland-headquartered drugmaker Shire (LSE: SHP) has had its patent upheld for Vyvanse (lisdexamfetamine) by the US Court of Appeals.

Several companies, including Actavis (NYSE: ACT) and Novartis’ (VX: NOVN) Sandoz unit were seeking Food and Drug Administration approval to market generic versions of Vyvanse. Shire filed many patent infringement lawsuits in 2011 and 2012, with the latest ruling upholding a lawsuit rendered in June 2014. It decided that 18 claims from four of the Vyvanse patents are valid and barred the defendant companies from launching Vyvanse generics until 2023 or later.

The drug was initially approved by the US FDA to treat attention-deficit hyperactivity disorder (ADHD) in children, later expanded to include an adult indication. Earlier this year it was approved for binge-eating disorder in adults.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK